Product Details

Veritra Capsules meet British Pharmacopoeia (BP) standards for the treatment of fungal infections. Specifically, each capsule delivers Itraconazole equivalent to 100mg. As a result, it offers broad-spectrum antifungal coverage for a range of superficial and systemic fungal infections.

The capsules contain:

• Itraconazole Capsules BP (equivalent to Itraconazole 100mg) – A triazole antifungal that inhibits fungal cytochrome P450-dependent enzymes essential for ergosterol synthesis. Consequently, it disrupts fungal cell membrane integrity, exerting fungistatic activity against a broad range of yeasts, dermatophytes, and moulds.

Physicians prescribe Veritra for the treatment of dermatophyte infections, onychomycosis (fungal nail infections), oral and vaginal candidiasis, and certain systemic fungal infections. In addition, its broad-spectrum activity makes it valuable for infections resistant to other antifungal agents. Because of this profile, Veritra suits dermatology, general practice, and specialist settings managing a wide range of fungal conditions.

Key Features:

• Overall, this BP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the oral capsule format supports convenient dosing across treatment courses
• Furthermore, each capsule delivers precise, validated dosage accuracy at 100mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, blister packaging protects capsule integrity against light and moisture
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies